Literature DB >> 17115258

Asymptotic theory for the Cox semi-Markov illness-death model.

Youyi Shu1, John P Klein, Mei-Jie Zhang.   

Abstract

Irreversible illness-death models are used to model disease processes and in cancer studies to model disease recovery. In most applications, a Markov model is assumed for the multistate model. When there are covariates, a Cox (1972, J Roy Stat Soc Ser B 34:187-220) model is used to model the effect of covariates on each transition intensity. Andersen et al. (2000, Stat Med 19:587-599) proposed a Cox semi-Markov model for this problem. In this paper, we study the large sample theory for that model and provide the asymptotic variances of various probabilities of interest. A Monte Carlo study is conducted to investigate the robustness and efficiency of Markov/Semi-Markov estimators. A real data example from the PROVA (1991, Hepatology 14:1016-1024) trial is used to illustrate the theory.

Entities:  

Mesh:

Year:  2007        PMID: 17115258     DOI: 10.1007/s10985-006-9018-9

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  9 in total

1.  Multi-state models for bleeding episodes and mortality in liver cirrhosis.

Authors:  P K Andersen; S Esbjerg; T I Sorensen
Journal:  Stat Med       Date:  2000-02-29       Impact factor: 2.373

2.  Confidence bands for comparison of transition probabilities in a Markov chain model.

Authors:  D M Dabrowska; W T Ho
Journal:  Lifetime Data Anal       Date:  2000-03       Impact factor: 1.588

3.  Robust inference for event probabilities with non-Markov event data.

Authors:  David V Glidden
Journal:  Biometrics       Date:  2002-06       Impact factor: 2.571

Review 4.  Modelling prevalence of a condition: chronic graft-versus-host disease after bone marrow transplantation.

Authors:  D Couper; M S Pepe
Journal:  Stat Med       Date:  1997-07-30       Impact factor: 2.373

5.  Covariance analysis of censored survival data.

Authors:  N Breslow
Journal:  Biometrics       Date:  1974-03       Impact factor: 2.571

6.  A study of the use of the probability-of-being-in-response function as a summary of tumor response data.

Authors:  C B Begg; M Larson
Journal:  Biometrics       Date:  1982-03       Impact factor: 2.571

7.  A qualifier Q for the survival function to describe the prevalence of a transient condition.

Authors:  M S Pepe; G Longton; M Thornquist
Journal:  Stat Med       Date:  1991-03       Impact factor: 2.373

8.  An analysis for transient states with application to tumor shrinkage.

Authors:  N R Temkin
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

9.  Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. The PROVA Study Group.

Authors: 
Journal:  Hepatology       Date:  1991-12       Impact factor: 17.425

  9 in total
  5 in total

1.  A semi-Markov multistate model for estimation of the mean quality-adjusted survival for non-progressive processes.

Authors:  Gisela Tunes-da-Silva; Antonio C Pedroso-de-Lima; Pranab K Sen
Journal:  Lifetime Data Anal       Date:  2008-12-10       Impact factor: 1.588

Review 2.  Inference for outcome probabilities in multi-state models.

Authors:  Per Kragh Andersen; Maja Pohar Perme
Journal:  Lifetime Data Anal       Date:  2008-09-13       Impact factor: 1.588

3.  Joint modeling approach for semicompeting risks data with missing nonterminal event status.

Authors:  Chen Hu; Alex Tsodikov
Journal:  Lifetime Data Anal       Date:  2014-01-16       Impact factor: 1.588

4.  A systematic model specification procedure for an illness-death model without recovery.

Authors:  Christine Eulenburg; Sven Mahner; Linn Woelber; Karl Wegscheider
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 5.  The wild bootstrap for multivariate Nelson-Aalen estimators.

Authors:  Tobias Bluhmki; Dennis Dobler; Jan Beyersmann; Markus Pauly
Journal:  Lifetime Data Anal       Date:  2018-03-06       Impact factor: 1.588

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.